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Abstract: The design, modeling, synthesis and biological activity evaluation of two hybrid agents 
formed by 7-oxyiminomethylcamptothecin derivatives and diaminedichloro-platinum (II) complex 
are reported. The compounds showed growth inhibitory activity against a panel of human tumor cell 
lines, including sublines resistant to topotecan and platinum compounds. The derivatives were 
active in all the tested cell lines, and compound 1b, the most active one, was able to overcome 
cisplatin resistance in the osteosarcoma U2OS/Pt cell line. Platinum-containing camptothecins 
produced Platinum-DNA adducts and topoisomerase I-mediated DNA damage with cleavage 
pattern and persistence similar to SN38, the active principle of irinotecan. Compound 1b exhibited 
an appreciable antitumor activity in vivo against human H460 tumor xenograft, comparable to that 
of irinotecan at lower well-tolerated dose levels and superior to cisplatin. The results support the 
interpretation that the diaminedichloro-platinum (II) complex conjugated via an oxyiminomethyl 
linker at the 7-position of the camptothecin resulted in a new class of effective antitumor 
compounds. 
 
Keywords: antitumor compounds; docking; camptothecin; diaminedichloro-platinum (II).  
 
*Corresponding Author: 
Phone +39 (2)50316818, Fax: +39 (2)50316801. E-mail: sabrina.dallavalle@unimi.it. 
___________________________________________________________________ 
 
 3
1. Introduction 
The antitumor activity of cis-diaminedichloro-platinum (II) (cisplatin or cDDP, Chart 1) was first 
reported by Rosenberg et al. in 1969 [1]. The success of cisplatin paved the way for the second and 
third-generation platinum(II) drugs, carboplatin and oxaliplatin (Chart 1). Presently, platinum-based 
coordination complexes are among the most widely used antitumor agents in the clinic [2].The 
effectiveness of cisplatin lies in its ability to covalently bind DNA, leading to important changes in 
the helical structure. In spite of the efficacy of platinum-based treatment regimens, long-term cure is 
difficult to obtain. The major drawbacks include a) severe and sometimes life-threatening toxic side 
effects; b) activation of drug resistance mechanisms by tumor cells; c) inadequate intratumor 
concentration of the drug and tumor microenvironmental interactions; d) relatively poor 
pharmacokinetic profiles and e) increased DNA repair capacity [3,4,5]. 
 
Chart 1  
Recently, major effort has been made to develop new platinum complexes. Often, the strategies 
were aimed to increase cellular uptake and/or facilitate targeting of the compounds to DNA [6].The 
latter approach involves the incorporation of a functional group into the platinum complex that 
interacts or intercalates with DNA. Numerous conjugates have been prepared in which the Pt 
moiety has been tethered to high-affinity nucleic acid ligands, such as doxorubicin [7], acridine [8], 
amines or peptides [9], anthraquinones [10] and short oligonucleotides [11]. In particular, a mixed 
platinum(II) complex with doxorubicin demonstrated antitumor activity against a variety of tumor 
cell lines, including doxorubicin- and cisplatin-resistant cell lines. Moreover, in contrast to the 
highly toxic doxorubicin/cisplatin combination, the doxorubicin-platinum complex was not 
associated to an increase in toxicity [7]. 
As part of our program aimed to advance DNA as a drug target, we were interested in devising 
novel platinum containing dual compounds that interacted in an effective way with DNA and in 
addition accomplished the requirements of solubility in the body fluids and improved cellular 
uptake. In this context, a promising approach seemed to be the conjugation of platinum to analogues 
of the natural antitumor compound camptothecin (CPT).  
CPTs [12] are widely used for the treatment of human cancers [13]. They exhibit a unique 
mechanism of action because they target the topoisomerase I (Topo I), forming a ternary complex 
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with the enzyme and DNA [14]. Stabilization of the cleavable complex and collision with the 
replication fork results in lethal double-strand breaks during DNA replication [15]. On the basis of 
this mechanism of action, the reversibility of drug-target interaction represents a limitation that 
results in resistance of slowly growing tumors. Intensive efforts in medicinal chemistry over the 
past decades have provided a large number of CPT analogues, of which topotecan (TPT) and 
irinotecan (prodrug of SN-38, Chart 2) are those so far approved for the clinical therapy [16].  
 
Chart 2 
Given the chemical interest of these agents [17], we planned to incorporate the two active 
compounds in a single “hybrid” molecule with the intention of exerting dual action and/or increase 
the drug-target interaction. The potential advantages of using CPT-Pt conjugates are multiple. On 
one hand, they could promote adequate cellular accumulation and nuclear localisation of the Pt(II)-
complex by virtue of the hydrophobicity of CPTs. On the other hand, the incorporation of a 
chemical function able to covalently bind to DNA, like a Pt moiety, could stabilize the CPT-DNA-
enzyme ternary complex, thereby improving the drug-target interaction.  
In the present, study we describe the synthesis, molecular modeling and biological evaluation of 
CPT-Pt complexes with different Pt-containing linkers. To the best of our knowledge, there are no 
examples in the literature of diaminedichloro-platinum (II) complexes tethered to CPT analogues. 
 
2. Results and discussion 
2.1 Chemistry and molecular modeling. The following criteria have guided the design of the 
CPT-Pt (II) conjugates: a) a CPT moiety substituted in a suitable position to maintain cytotoxic 
activity; b) a linker between the Pt center and the CPT skeleton, chosen to ensure enough 
conformational flexibility while maintaining proximity of the reactive metal center to the DNA-
selective scaffold; c) a chelating diamine selected to secure Pt (II) coordination to the CPT moiety.  
Recently, a series of CPTs substituted in position 7 have been synthesized in our laboratory. The 
compounds exhibited potent cytotoxic activity in vitro and in vivo comparable or superior to TPT 
[18-20]. The highest activity was shown by oxyiminomethyl derivatives, even when bulky [19] and 
long-chain [20] substituents were introduced. Some compounds gave promising results in 
preclinical [21] and clinical [22] studies. In contrast, incorporation of the same groups in position 9 
caused a drop in cytotoxic activity [23]. 
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For this reason, (E)-7-oxyminomethyl CPTs were selected for conjugation to Pt(II) [19]. Initially, 
we focused on the most promising 7-substituted compound in our hands, 3a (Figure 1). As the 
molecule is characterized by a terminal amino group, we planned to link the CPT moiety to Pt(II) 
through an amide bond. Thus, the synthesis of compound 1a (Figure 1), designed as our first 
conjugate, was devised to proceed by coupling of 3a with 2,3-diaminopropionic acid followed by 
complexation of the derived diamine (2a) with a suitable platinum salt .  
Figure 1 
Prior to start the synthesis, we studied the binding mode of compound 1a to the Topo I covalent 
complex with DNA [24]. A two-step protocol was used to obtain a better estimate of the orientation 
of the ligands within the binding site. First, the non-platinated ligands were correctly placed within 
the binding site using the molecular docking technique. On the basis of the geometry of interaction 
thus obtained, the platinated ligands were built and analyzed using the QM/MM approach. To gain 
insight into the role of the linker on the interaction with the target, we also modelled the binding of 
a series of derivatives 1 with different carbon chain length (n= 1-4). Molecular modelling showed 
that the compound with six carbons (n = 3, 1b) demonstrated the best interactions. Thus, for the 
sake of clarity, here we describe only the target-drug interactions of compound 1b compared to 1a.  
The intercalation binding site for all of the studied compounds was located between the +1 
(upstream) and -1 (downstream) base pairs of the uncleaved strand, which effectively ‘‘open’’ the 
DNA duplex. Comparative analysis of the best poses obtained for the four non-platinum-containing 
compounds (2a-b, 3a-b) revealed their common behavior of intercalating at the site of DNA 
cleavage, forming base-stacking interactions with both the -1 and +1 base pairs. There is evidence 
of two direct hydrogen bonds between the Asp533 and Arg364 residues of the enzyme and the planar 
skeleton of the investigated derivatives, in perfect agreement with the CPT-DNA complex structure 
[24]. The greatest differences were found by analyzing the behavior of the side chains. For 2a, the 
side chain was too short and allows only a partial interaction with the DNA duplex, leading one of 
the two amino groups to interact with O6 and N7 of G11, whereas the immine nitrogen interacts 
weakly with N6A113. For both 2b and 3b, the greater length of their side chains allows them to 
interact more efficiently with the DNA duplex. The amino group of 3b forms three strong hydrogen 
with N7G11, whereas 2b forms a hydrogen bond to N6A113, two between the amino group and O6G12 
and the last with N7G11. The interactions between derivatives 2a and 2b and the DNA-Topo I 
complex are given in Figure 2 (together with the experimental DNA-Topo I structure (PBD code 
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1T8I), where the interactions listed as dotted green lines represent the intermolecular hydrogen 
bonds.  
Figure 2 
 
Orientations of the systems described above (2a and 2b) were used to assemble the two Pt 
complexes (1a and 1b), which were further analyzed using the QM/MM mixed approach on the 
platinated complexes. This QM/MM mixed approach allowed us to obtain a better and more 
complete description of the interactions of the two Pt complexes with the DNA-Topo I system, as 
well as an evaluation of the structural changes induced in the complex by the binding of ligands 1a 
and 1b. Major differences were observed at the level of the side chain, whereas the CPT ring 
maintained its position inside the DNA-Topo I system (Figure 3).  
 
Figure 3 
 
The compound with the longer spacer (1b) is more effective in its interaction with the DNA duplex 
than the one with the shorter side chain (1a). Both complexes are stabilized by the formation of two 
hydrogen bonds between O6G12 and an amino group bound to the platinum atom that lies in the 
square planar coordination plane with a small distortion of the Pt-N7 bond due to the destacking of 
the bases. Compound 1b is further stabilized by two interactions with N7G11 and N6A113, the same 
as those previously discussed for 2b. Indeed, the complex formation induces a distortion of the 
DNA duplex, with a partial destacking of the nucleotide bases, which is less marked in the case of 
compound 1b. The shift of G12 in the complex with 1a is significantly larger (7.1 Å) than in the 
complex with 1b (5.4 Å), in poor agreement with the guanine position in the crystal structure. 
Moreover, the hydrophobic face of the guanine base for 1a is even more solvent exposed than for 
1b, giving rise to an additional source of instability of the 1a complex.  
It should be noted that in Figures 2 and 3, the best poses for derivatives 1 and 2 with only S absolute 
configuration at the stereogenic center on the diamine moiety are reported. The best poses for the 
corresponding R diastereomers did not show striking differences with regard to chirality, indicating 
that the stereochemistry of the diamine moiety does not seem to play a role in the interaction with 
DNA.  
On the basis of molecular modeling results, the synthesis of compounds 1a and 1b was carried out. 
Compound 1a was prepared from the corresponding 7-oxyminomethylCPT 3a [19], which in turn 
was obtained from 7-formylCPT (4). The oxime was then condensed with N,N-bis-t-
butoxycarbonyl-2,3-diaminopropanoic acid in the presence of WSC and HOBt as condensing 
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agents. The Boc-diamine 5a was quantitatively deprotected with TFA in CH2Cl2 to obtain the 
bistrifluoroacetate 6a. Reaction with K2PtCl4 [25] afforded 1a in 69% yield (Scheme 1).  
 
Scheme 1 
 
The synthesis of compound 1b required the preparation of the longer-chain hydroxylamine 8 
(Scheme 2). Protection of 6-aminohexanol with (Boc)2O, followed by Mitsunobu reaction with N-
hydroxyphthalimide, afforded compound 7. Hydrazinolysis and subsequent deprotection from the 
Boc group with 5.9 M HCl at 0°C afforded hydroxylamine 8 hydrochloride. Condensation with 7-
formylCPT (4) by refluxing in ethanol in the presence of pyridine afforded oxime 3b.  
Following the same synthetic approach described for compound 1a, the bistrifluoroacetate 6b was 
obtained in 65% overall yield from 3b. Disappointingly, in this case the reaction with K2PtCl4 gave 
compound 1b in low yield and unsatisfactory purity, due to a troublesome separation of the desired 
compound from the salt 6b. Thus, a different strategy was followed. The cis-
dichlorobis(diaminopropionic acid hydrochloride) platinum (II) complex was first prepared in high 
yield by reacting 2,3-diaminopropionic acid hydrochloride with K2PtCl4 in H2O [26] and then 
condensed with 3b to give 1b in 89% yield (Scheme 2). 
 
Scheme 2 
 
2.2 Antiproliferative activity studies. The antiproliferative effect of the derivatives 1a-b and 6a-b 
was determined at 1 h exposure on different human tumor cell lines, including cell lines resistant to 
TPT and platinum compounds (Table 1). TPT and cDDP were used as reference drugs. All the 
tested compounds were generally more potent than cDDP on all the selected cell lines, including 
those resistant to cDDP, oxaliplatin and TPT. In contrast, a comparison between the new CPT-Pt 
derivatives and TPT revealed cell line-dependent drug potency. A superior cytotoxicity with respect 
to TPT was evidenced for 1b and 6b on the H460 cell line, since 6a and 1a are less potent than 
TPT. All the compounds were less potent that TPT in the squamous cell carcinoma A431 cell line, 
including the corresponding sublines resistant to TPT (A431/TPT) and cDDP (A431/Pt). The 
compounds were less potent than TPT in the osteosarcoma U2OS cell line and, with the exception 
of 1b, such behavior was observed also in the corresponding cDDP-resistant variant (U2OS/Pt). A 
general reduced potency with respect to TPT was observed in ovarian carcinoma IGROV-1 and 
A2780 cell lines. This was also evident in the corresponding cDDP and oxaliplatin-resistant 
sublines with the exception of 1b in IGROV-1/Pt and 1b and 6b in IGROV-1/OHP cells. 
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Table 1 
 
As regards the resistance index (ratio between IC50 values of resistant and sensitive cells), the 
contribution of the Pt(II) complex was demonstrated by the reduced resistance indexes observed for 
CPT-Pt derivatives with respect to cDDP and TPT in several human tumor cell lines. The resistance 
index of CPT-Pt (1a and 1b) was higher than that of cDDP and TPT in A431/TPT cells. 
Conversely, a reduced resistant index with respect to TPT and cDDP was observed for the two 
hybrid compounds in A431/Pt, U2OS/Pt, IGROV-1/Pt, IGROV-1/OHP and A2780/CP cells.  
It is noteworthy that the most active derivative 1b was effective in overcoming cDDP resistance in 
osteosarcoma cDDP-resistant U2OS cells (Table 1 and Figure 4). 
 
Figure 4  
 
To clarify the role of the Pt(II) complex in drug activity, the ratio between the IC50 of compounds 
not containing Pt and the IC50 of compounds containing Pt (6a/1a or 6b/1b) was considered. A ratio 
higher than 1 indicates the positive effect produced by the Pt atom. As reported in Figure 4, the role 
of the Pt atom appears more important for the potency of 1b than for 1a. Indeed, considering the 11 
cell lines evaluated, the ratios were < 1 in six cell lines for 6a/1a and only in two cell lines for 
6b/1b. 
 
2.3 Drug combination studies. Drug combination experiments using platinum compounds with 
CPTs are widely documented [27]. Synergism was evidenced in various human tumor cell lines 
[27]. Indeed, the presence of Pt-DNA adducts in the substrate DNA inhibited Topo I activity, 
whereas it enhanced CPT action on the cleavable complex [28]. The effect of the combination of 
cDDP and our derivatives (6a-b) on antiproliferative activity was evaluated on the H460 cell line 
(Figure 5). To this purpose, cells were simultaneously exposed for 1h to increasing concentrations 
of CPTs and to subtoxic concentration (10 µM) of cDDP (Figure 5).The data demonstrated that, as 
for the combination of cDDP with TPT, the combination of 6a-b with cDDP resulted in a 
synergistic interaction, thus supporting the rational of joining the two moieties into a single 
molecule. 
 
Figure 5  
 
2.4 Topoisomerase I-dependent DNA cleavage assay. TopoI-mediated DNA cleavage 
experiments were performed to investigate the ability of the new compounds to stimulate DNA 
 9
damage. SN38 was used as reference compound. As reported in Figure 6, a dose-dependent 
precipitation of labeled DNA in the wells was observed for CPT-Pt derivatives (1a and 1b). This 
behavior was drug- and enzyme-dependent since it was not observed in the presence of cDDP, 6b, 
or in the absence of TopoI. 
 
Figure 6 
 
Stabilization of the ternary cleavable complex was evaluated by adding a high salt concentration 
(0.6 M NaCl) after 30 min of incubation in the presence of the tested compound. The high salt 
concentration favors the dissociation of the drug-enzyme-DNA complex, thus producing evidence 
of the stability of the ternary complex. The stability of the cleavage complex was evaluated at 1 µM 
drug concentration. It was not possible to evaluate the stability of the cleavable complex at 10 µM 
drug concentration since the accumulation of the labeled DNA into the wells was not reversed (data 
not shown). The cleavage persistence evaluated at 1 µM indicated that CPT-Pt 1b and 1a induced a 
persistent cleavage stability with respect to SN38. Such behavior was less evident when CPT-Pt 
compounds were compared with the corresponding derivatives lacking Pt (6a and 6b) (Figure7). 
 
Figure 7 
 
2.5 Drug uptake and DNA platination. Drug uptake and DNA platination were evaluated in H460 
cells exposed for 1 h to equitoxic (IC50 cDDP = 22 µM; 1a = 4.1 µM; 1b = 0.4 µM) or equimolar 
(0.4 µM) concentrations of compounds. cDDP was used as reference drug. As reported in Figure 
8A, at equitoxic concentrations a marked cellular uptake of 1a was observed. It is noteworthy that 
the uptake of 1b was comparable to that of cDDP, in spite of its 55-fold lower concentration. As 
regards the exposure to equimolar drug concentration (0.4 µM), a significantly higher cellular Pt 
accumulation was evidenced for 1a (P< 0.02) and 1b (P< 0.01) with respect to cDDP (Figure 8B). 
DNA platination was studied in H460 cells exposed for 1 h to equitoxic (IC50) concentrations of 
compounds. Pt-DNA adducts were revealed in the DNA extracted from cells treated with both 1a 
and 1b (Figure 8C). DNA-bound Pt was significantly higher in cells exposed to cDDP than 1a and 
1b (P< 0.02). The finding is expected, because the low potency of cDDP required the use of 
substantially higher concentrations (IC50 cDDP = 22 µM). In contrast, the exposure of H460 cells to 
equimolar concentration of drugs (0.4 µM) resulted in DNA platination only in cells treated with 1b 
(data not shown).  
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Figure 8 
 
2.6 Viability and DNA platination of yeast cells expressing human DNA topoisomerase I. The 
S. cerevisiae JN2-134 strain, which lacks endogenous DNA TopoI, was used. Yeast cells 
transformed with the empty vector (pEMBLyex4) or with the same vector containing the entire 
ORF of the human DNA Topo I (pEZ-2hTop1) were treated with CPTs (1a-b, 6a-b) for 24 h and 
then plated according to the yeast spot test (Figure 9). CPT and cDDP were used as references. 
cDDP exhibited similar growth inhibitory potency on both pEMBLyex4 and pEZ-2hTop1 
transformed yeasts, indicating that cDDP potency was unaffected by the presence/absence of TopoI. 
Conversely, cell growth of yeast cells expressing human TopoI was affected by the exposure to 
CPTs (1a-b, 6a-b). No important change in cell growth was observed for yeast cells transformed 
with the empty vector and treated with CPTs. Interestingly, a significant increase (P< 0.01) in DNA 
platination was documented in yeasts expressing human TopoI and treated with CPT-Pt with 
respect to yeasts transformed with empty vector (Figure 9B). Altho 
ugh less relevant, a significant change (P< 0.02) in the amount of Pt-DNA adducts was also 
observed for transformed yeasts treated with cDDP. 
 
Figure 9 
 
2.7 Effect of DNA Topoisomerase I on the formation of Pt-DNA adducts. CPT derivatives (1a-
b, 6a-b) were tested for their capability to bind the DNA by evaluating the migration of pCMV6neo 
plasmid in agarose gel electrophoresis after drug exposure (Figure 10). In comparison to cDDP and 
SN38, which did not produce any effect on DNA migration, the exposure of plasmid DNA to 1a 
revealed a significantly reduced migration of the vector. Such behavior was likely dependent on the 
major capability of 1a to produce Pt-DNA adducts. The effect was less marked for 1b. Moreover, 
the simultaneous exposure of pCMV6neo plasmid to TopoI and 1a or 1b produced DNA 
accumulation in the wells, thus resembling that observed in cleavage assays. Such behavior was 
dependent on the presence of TopoI, since it was not observed in the absence of enzyme or in the 
presence of human serum albumin (BSA). Interestingly, degradation of the protein by SDS and 
proteinase K before loading on agarose gel produced a different behavior depending on the 
compound. No change in DNA migration was evidenced with respect to un-proteolized sample for 
plasmid exposed to 1b, whereas a migration similar to the control was obtained when DNA treated 
with 1a and TopoI was exposed to SDS/proteinase K before loading. 
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To evaluate the effect of TopoI on platination of the plasmid DNA, pCMV6neo was exposed to 1b 
or cDDP in the presence and absence of TopoI in a cell-free system. As reported in Figure 10B, the 
Pt-DNA adducts were significantly increased by the addition of purified human TopoI in the 
presence of both cDDP (P< 0.05) and 1b (P< 0.02). 
 
Figure 10 
 
2.8 In vivo antitumor activity. On the basis of the promising results observed in vitro, compound 
1b was selected for further preclinical development. Mice bearing non-small cell lung cancer H460 
carcinoma tumor xenograft were treated with 1b administered intravenously (i.v.) according to the 
intermittent q4dx4 schedule (Table 2.). Compound 1b exhibited antitumor activity comparable to 
that of irinotecan and higher than that of cDDP, both delivered at their maximum tolerated doses. 
Considering the toxicity profile, 1b was well tolerated (no lethal toxicity and no body weight loss) 
with respect to cDDP (1/5 toxic deaths). 
 
Table 2 
 
3. Conclusions 
 
Platinum drug administration is associated with dose-limiting side effects, off-target effects and 
relatively poor pharmacokinetic profiles. In particular, the low cellular uptake and the rapid 
metabolic inactivation of platinum compounds imply that the amount of active drug reaching the 
target is low. As regards CPTs, the reversibility of the DNA cleavage may represent a limitation of 
drug efficacy, resulting in resistance of slowly growing tumors. In an attempt to overcome such 
drawbacks, hybrid 7-oxyiminomethyl CPTs containing a Pt(II) complex were synthesised. 
Molecular modeling studies evidenced that the CPT moiety of the hybrid drugs overlapped TPT in 
the cleavable complex, independently of the absolute configuration of the stereogenic center on the 
diamine moiety. The most efficient interaction with duplex DNA was observed for compound 1b, 
thus supporting a critical role of the linker to provide drug-DNA interaction. CPT-Pt derivatives 
were effective antiproliferative agents, with potency similar/superior to TPT and in general more 
potent than cDDP. The potential advantage of the Pt(II) complex was also supported by the reduced 
resistance indexes observed for CPT-Pt derivatives with respect to cDDP and TPT in several human 
tumor cell lines. It is noteworthy that the most active derivative 1b was effective in overcoming 
cDDP resistance in osteosarcoma cDDP-resistant U2OS cells. More importantly, CPT-Pt exhibited 
activity both as a Topo I poison and as a DNA-platinating molecule, thus indicating that the 
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conjunction of the two components in a one hybrid molecule did not negatively impact on their 
properties as single drugs. Interestingly, results obtained in a cell-free system and in experiments 
involving yeast cells documented two relevant findings produced by the presence of Topo I: i) DNA 
platination produced by the CPT-Pt molecules was increased in the presence of Topo I, and ii) the 
presence of Topo I, but not BSA, produced a dose-dependent accumulation of DNA in the wells of 
agarose and acrylamide gels, thus evoking a network organization involving DNA, CPT-Pt and 
Topo I. It could be speculated that the network effect observed at a high concentration might be the 
result of CPT-Pt acting outside, rather than inside, the active site of Topo I. Thus, a scenario in 
which the Pt atoms form covalent bounds linking the DNA and the Topo I outside the active site 
should be considered as a possible alternative/additional mechanism of drug action. This aspect 
remains to be properly investigated. 
Concerning antitumor activity, preliminary in vivo data indicated that compound 1b was well 
tolerated and exhibited promising antitumor potency, comparable to that of irinotecan and superior 
to that of cDDP. The widely used combinations of CPTs with platinum compounds exhibit 
synergism in terms of both efficacy and toxicity. Thus, the good profile of tolerability of the CPT-Pt 
complex supports additional therapeutic advantages over the drug combinations. 
In conclusion, results of the study provide evidence that CPT and a Pt(II) complex joined in a single 
molecule via an oxyiminomethyl linker could be considered a new class of effective antitumor 
compounds. 
 
4. Experimental section 
 
4.1 Chemistry. General Methods. All reagents and solvents were reagent grade or were purified by 
standard methods before use. Melting points were determined in open capillaries. NMR spectra 
were recorded with a Bruker AMX 300 spectrometer using TMS as an internal standard. Chemical 
shifts are given in ppm (δ). Mass spectra were recorded with a Fourier transform ion cyclotron 
resonance (FT-ICR) mass spectrometer APEX II & Xmass software (Bruker Daltonics)-4.7T 
Magnet (Magnex). The Elemental Analyses were recorded with a CARLO ERBA EA 1108 
instrument.  Solvents were routinely distilled prior to use; anhydrous tetrahydrofuran (THF) and 
ether (Et2O) were obtained by distillation from sodium–benzophenone ketyl; dry dichloromethane 
was obtained by distillation from phosphorus pentoxide. All reactions requiring anhydrous 
conditions were performed under a positive nitrogen flow, and all glassware were oven dried and/or 
flame dried. Isolation and purification of the compounds were performed by flash column 
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chromatography on silica gel 60 (230–400 mesh). Analytical thin-layer chromatography (TLC) was 
conducted on TLC plates (silica gel 60 F254, aluminum foil). 
4.1.1 {2-tert-Butoxycarbonylamino-1-[2'-(camptothecin-7-
ylmethyleneaminooxy)ethylcarbamoyl]ethyl}carbamic acid tert-butyl ester (5a) To a solution of 
N,N-bis-t-butoxycarbonyl-2,3-d,l-diaminopropanoic acid [25] (134 mg, 0.441 mmol) in anhydrous 
DMF (6.6 mL) at 0°C under nitrogen, HOBt (103 mg, 0.750 mmol) and WSC (103 mg, 0.523 
mmol) were added. After stirring for 30 min at 0°C, the solution was added with 3a (157 mg, 0.362 
mmol) and DIPEA (165 mg, 1.28 mmol) and stirred for 2.5 h at room temperature. The solvent was 
evaporated and water was added (4 mL). The precipitate was filtered and dried. Purification by 
flash chromatography (CH2Cl2/ MeOH 95:5) afforded the title compound as a yellow solid (yield 
77%); mp 148 °C; Rf 0.36 (CH2Cl2/ MeOH 95:5). 1H NMR (DMSO-d6) δ: 9.30 (s, 1H); 8.60 (d, J = 
8.6 Hz, 1H); 8.25 (d, J = 8.6 Hz, 1H); 8.11 (brs, 1H); 7.98-7.85 (m, 1H); 7.85-7.70 (m, 1H); 7.39 (s, 
1H); 6.80-6.60 (m, 2H); 6.50 (s, 1H); 5.48 (s, 2H); 5.39 (s, 2H); 4.38 (t, J = 6.9 Hz 2H); 4.03-3.97 
(m, 1H); 3.70-3.50 (m, 2H); 3.25-3.10 (m, 2H); 198-1.80 (m, 2H); 1.38 (s, 18H); 0.87 (t, J = 7.0 Hz, 
3H). 13C-NMR (CDCl3) δ: 173.6, 171.0, 157.3, 156.9, 156.1, 152.0, 150.1, 149.3, 148.6, 145.7, 
144.1, 130.8, 130.5, 128.4, 125.8, 125.1, 122.7, 118.8, 97.9,73.9, 73.5, 72.7, 66.2, 55.8, 42.5, 38.9, 
31.5, 28.2, 24.8, 7.7. HRMS(ESI+): [M+Na]+ calcd for C36H45N6O10 721.3192; found 721.3163. 
Anal. calcd for C36H44N6O10: C, 59.99; H, 6.15; N, 11.66. Found: C, 59.76; H, 5.93; N, 11.81. 
4.1.2 2,3-d,l-Diamoniumtrifluoroacetate-N-[2'-(camptothecin-7-ylmethyleneaminooxy)-ethyl]-
propionamide (6a). TFA (2.75 mL) was dropped into a solution of 5a (138 mg, 0.27 mmol) in 
CH2Cl2 (2.7 mL) at 0°C. The resulting orange solution was stirred for 3 h at room temperature. The 
solvent was evaporated and Et2O was added to obtain a precipitate. The solid was filtered and 
washed three times with Et2O then dried to give the title compound as a yellow solid in quantitative 
yield; mp 120°C. 1H NMR (DMSO-d6) δ: 9.35 (s, 1H); 8.90 (brs, 1H); 8.60 (d, J = 8.6 Hz, 1H); 
8.50-8.00 (brm, 7H); 7.99-7.92 m, 1H); 7.90-7.82 (m, 1H); 7.39 (s, 1H); 6.60 (brs, 1H); 5.50 (s, 
2H); 5.35 (s, 2H); 4.44 (t, J = 7 Hz, 2H); 4.22-4.12 (m, 1H); 3.70-3.65 (m, 1H); 3.65-3.50 (m, 1H); 
3.35-3.20 (m, 2H); 1.95-1.80 (m, 2H); 0.87 (t, J = 7.0 Hz, 3H). 13C-NMR (DMSO-d6) δ: 172.8, 
166.9, 166.0, 159.3, 158.8, 157.1, 152.8, 150.5, 149.0, 146.1, 145.5, 131.2, 130.9, 130.3, 128.8, 
127.2, 125.3, 124.4, 119.7, 97.4, 97.0, 73.4, 72.8, 65.6, 65.2, 52.5, 50.6, 40.1, 30.7, 8.2. 
HRMS(ESI+): [M-2CF3COO-]+ calcd for C26H30N6O6 522.2221; found 522.2287. Anal. calcd for 
C30H30 F6N6O10: C, 48.13; H, 4.04; N, 11.23. Found: C, 47.90; H, 3.91; N, 10.85. 
4.1.3 Dichloro{2,3-d,l-diamino-N-[2'-(camptothecin-7-ylmethyleneaminooxy)-ethyl]-
propionamide}platinum (II) (1a). A solution of K2PtCl4 (44 mg, 0.11 mmol) in water (0.40 mL) 
was prepared under a stream of nitrogen. The aqueous solution was added to a solution of 
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compound 2a (80 mg, 0.11 mmol) in water (2 mL) and the resulting mixture was stirred in the dark 
at room temperature under nitrogen for 3 h. The orange precipitate formed was filtered and washed 
twice with water, then with methanol and with Et2O. After drying under vacuum the title compound 
was obtained as a yellow solid (yield 69%); mp 255°C; Rf 0.30 (CH2Cl2/MeOH 7:1); 1H NMR 
(DMSO-d6) δ: 9.33 (s, 1H); 8.62 (d, J = 8.6 Hz, 1H); 8.50 (brs, 1H); 8.25 (d, J = 8.6 Hz, 1H); 8.00-
7.79 (m, 1H); 7.85-7.75 (m, 1H); 7.40 (s, 1H); 6.58 (brs, 1H); 5.82 (brs, 1H); 5.49 (s, 2H); 5.40 (s, 
2H); 5.11 (brs, 1H); 4.40 (t, J = 7.0Hz, 2H); 3.70-3.50 (m, 3H); 3.40-3.30 (m, 2H), 1.95-1.80 (m, 
2H); 0.87 (t, J = 7.0 Hz, 3H). 13C-NMR (DMSO-d6) δ 172.9, 167.9, 167.0, 157.1, 152.9, 150.5, 
149.1, 146.3, 145.6, 131.0, 130.3, 128.8, 127.4, 125.4, 124.7, 119.7, 97.2, 73.5, 72.8, 65.6, 61.7, 
52.6, 40.7, 39.0, 30.6, 8.2. HRMS(ESI+): [M+Na]+ calcd for C26H28Cl2N6NaO6Pt 808.0987; found: 
808.0958. Anal. calcd for C26H28 Cl2N6O6Pt: C, 39.70; H, 3.59; Cl, 9.02; N, 10.69, Pt 24.80. Found: 
C, 39.82; H, 3.44; Cl, 9.35; N, 10.33; Pt 24.40.  
4.1.4 [6-(1,3-Dioxo-1,3-dihydro-isoindol-2-yloxy)hexyl]carbamic acid tert-butyl ester (7). To a 
solution of (6-hydroxyhexyl)carbamic acid tert-butyl ester [29] (730 mg, 3.36 mmol), 
triphenylphosphine (1.173g, 4.48 mmol) and N-hydroxyphthalimide (731 mg, 4.48 mmol) in THF 
(45 mL) at 0°C, diisopropyl azodicarboxylate (906 mg, 4.48 mmol) was dropped. After stirring 
overnight at room temperature, the solvent was evaporated and the residue was purified by flash 
chromatography (hexane/ethylacetate 3:7 then hexane/ethylacetate 2:8) and successively 
crystallized from MeOH to give the title compound as a white solid (yield 82%); mp 166°C. Rf 0.34 
(CH2Cl2/ MeOH 95:5). 1H NMR (CDCl3) δ: 7.89-7.67 (m, 4H); 4.61 (brs, 1H); 4.15 (t, J = 6.7 Hz 
2H); 3.18-3.00 (m, 2H); 1.41 (s, 9H); 1.85-1.20 (m, 8H). 13C-NMR (CDCl3) δ 163.6, 156.0, 134.4 
(x2), 128.9 (x2), 123.4 (x2), 78.3, 70.0, 40.4, 29.8, 28.4, 28.2, 28.0, 26.3, 25.2, 21.9.. HRMS (ESI+): 
[M+Na]+ calcd for C19H26N2NaO5 385.1734; found 385.1779. Anal. calcd for C19H26N2O5: C, 
62.97; H, 7.23; N, 7.73. Found: C, 62.81; H, 7.02; N, 7.98. 
4.1.5 O-(6-aminohexyl)hydroxylamine dihydrochloride (8). To a solution of compound 7 (1.260 g, 
3.48 mmol) in MeOH (10.2 mL), hydrazine hydrate (0.522 g, 10.44 mmol) was added. The 
resulting mixture was refluxed for 1 h. The white solid was filtered, the solvent evaporated and the 
residue purified by flash chromatography (CH2Cl2: MeOH 99:1) to give (6-
aminooxyhexyl)carbamic acid tert-butyl ester as a colorless oil in quantitative yield. Rf 0.25 
(CH2Cl2/MeOH 95:5).1H NMR (CDCl3) δ: 6.32 (brs, 1H); 4.01 (t, J = 6.6 Hz 2H); 3.15-3.02 (m, 
2H); 1.44 (s, 9H), 1.89-1.20 (m, 8H). 13C-NMR (CDCl3) δ: 156.1, 77.8, 75.2¸ 44.6, 29.8, 28.7 (x2), 
28.6, 26.5, 25.7, 22.1. HRMS (ESI+): [M+Na]+ calcd for C11H25N2O3 233.1860; found 233.1845. 
To a solution of the above tert-butyl ester (389 mg, 1.67 mmol) in AcOEt (2.8 mL) at 0°C, a 5.9 M 
solution of HCl in AcOEt was dropped. After 1 h at 0°C the solvent was evaporated to obtain the 
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title compound as a white solid (yield 97%); Rf 0.15 (CH2Cl2/MeOH 9:1). 1H NMR (DMSO-d6) δ: 
10.90 (brs, 3H); 7.91 (brs, 3H); 3.97 (t, J = 6.7 Hz, 2H); 2.80-2.65 (m, 2H); 1.61-1.43 (m, 4H); 
1.37-1.21 (m, 4H). 13C-NMR (DMSO-d6) δ: 74.2, 27.3, 27.1, 25.7, 24.9 (one peak missing due to 
overlapping with solvent signal). The compound was used without further purification for the next 
step. 
4.1.6 7-(6-aminohexyloxyiminomethyl)camptothecin (3b). To a suspension of camptothecin-7-
carbaldehyde (4) (150 mg, 0.39 mmol) in EtOH (3.8 mL) compound 8 (163 mg, 0.79 mmol) and 
pyridine (0.65 mL) were added. The resulting mixture was heated at reflux for 1 h, then the solvent 
was evaporated. The pure title compound was obtained as a yellow solid after crystallization from 
Et2O/EtOH. (yield 77%); mp 80°C; Rf 0.20 (CH2Cl2/MeOH 90:10). 1H NMR (DMSO-d6) δ: 9.31 (s, 
1H); 8.60 (d, J = 8.5 Hz 1H); 8.20 (d, J = 8.5 Hz, 1H); 7.98-7.61 (m, 4H); 7.34 (s, 1H); 6.53 (brs, 
1H); 5.42 (s, 2H); 5.29 (s, 2H); 4.34 (t, J = 6.7 Hz, 2H); 2.86-2.63 (m, 2H); 1.96-1.75 (m, 4H); 
1.69-1.40 (m, 6H); 0.87 (t, J = 6.7 Hz, 3H). ); 13C-NMR (75 MHz, DMSO-d6) δ 168.6, 166.8, 
157.1, 152.9, 150.5, 149.1, 146.5, 145.6, 131.0, 130.3, 128.7, 127.4, 125.4, 124.7, 119.7, 97.2, 74.4, 
72.8, 65.6, 52.6, 44.0, 31.3, 30.7, 28.2, 27.5, 26.8, 8.2. HRMS (ESI+): [M+H+] calcd for 
C27H31N4O5 491.2289; found 491.2266. Anal. calcd for C27H30N4O5: C, 66.11; H, 6.16; N, 11.42. 
Found: C. 66.32; H. 6.00; N. 11.63. 
4.1.7 Dichloro{2,3-d,l-diamino-N-[2'-(camptothecin-7-ylmethyleneaminooxy)-hexyl]-
propionamide}platinum (II) (1b). To a solution of 7-(6-aminohexyloxyiminomethyl)CPT (70 mg, 
0.14 mmol) and dichloro[(d,l)-diaminopropionic acid]platinum(II) [26] (106 mg, 0.29 mmol) in dry 
DMF (7 mL), EDC (137 mg, 0.71 mmol) and TEA (5 drops) were added under nitrogen. The 
resulting mixture was strirred at room temperature for 24 h in the dark. The solvent was evaporated 
and water was added. The suspension was heated to 60°C, and the yellow precipitate was filtered 
(yield 89%); mp 197°C. Rf 0.37 (CH2Cl2/MeOH /TEA 90:10: 0.1). 1H NMR 600 MHz (DMSO-
d6) δ: 9.32 (s, 1H); 8.59 (d, J = 8.6 Hz, 1H); 8.20 (d, J = 8.6 Hz, 1H); 8.11 (brs, 1H), 7.95-7.80 (m, 
1H); 7.80-7.72 (m, 1H); 7.34 (s, 1H); 6.52 (s, 1H); 5.79 (brs, 1H); 5.45-5.35 (m, 3H); 5.37 (s, 2H); 
5.00 (brs, 1H); 4.33 (t, J = 7.0 Hz, 2H); 3.40-3.25 (m, 2H); 3.18-3.00 (m, 2H); 1.90-1.75 (m, 5H); 
1.60-1.10 (m, 5H); 0.87 (s, 3H). 13C-NMR 150 MHz (DMSO-d6) δ 187.2, 172.8, 166.5, 157.1, 
152.9, 150.4, 149.1, 145.6, 145.2, 131.5, 130.9, 130.2, 128.7, 127.2, 125.4, 124.6, 119.6, 97.1, 75.3, 
72.8, 65.6, 61.4, 52.6, 50.0, 30.7, 29.1, 29.0, 26.5, 25.4, 8.1. HRMS(ESI+): [M+Na]+ calcd for 
C30H36Cl2N6NaO6Pt 864.1613; found: 864.1601. Anal. calcd. for C30H36Cl2N6O6Pt: C 42,76; H 
4,31; Cl 8,41; N. 9,97; Pt, 23.15; found C 42,91; H 4,06; Cl 8,25; N. 9,69; Pt, 23.30. 
4.2 Molecular modeling. The five studied camptothecin derivatives were assembled and refined 
using a systematic conformer search followed by geometry optimization of the lowest energy 
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structure with MOPAC (PM3 Method, RMS gradient 0.0100) [30]. The macromolecule (PDB 
deposition code: 1T8I) was prepared by removing the camptothecin molecule and adding polar 
hydrogen atoms, while the side chains of the disordered amino acid residues of the macromolecule 
complex were checked and rebuilt in DeepView [31]. The individual compounds were pre-
positioned based on the coordinates of camptothecin from the X-ray structure.  
The small molecule compounds and the macromolecule were further processed using the Autodock 
Tool Kit (ADT) [32]. Gasteiger–Marsili charges [33] were loaded on the small molecules in ADT 
and Cornell parameters used for the phosphorus atoms in the DNA. Solvation parameters were 
added to the final macromolecule structure using Addsol utility of Autodock. All docking runs were 
performed with Autodock 4 [34], using an empirical free energy function and Lamarckian Genetic 
Algorithm, with an initial population of 50 randomly placed individuals, a maximum number of 200 
energy evaluations, a mutation rate of 0.02, a crossover rate of 0.80, and an elitism value of 1. For 
the local search, the so-called pseudo-Solis and Wets algorithm was applied using a maximum of 
250 iterations per local search. The probability of performing local search on an individual in the 
population was 0.06, and the maximum number of consecutive failures before doubling or halving 
the local step size was 4. Fifty independent docking runs were carried out for each ligand. Results 
differing by less than 1.0 Å in positional root-mean-square deviation (rmsd) were clustered together 
and represented by the result with the most favorable free energy of binding. The grid maps 
representing the protein in the actual docking process were calculated with Autogrid. The grids (one 
for each atom type in the ligand, plus one for electrostatic interactions) were chosen to be 
sufficiently large to include the entire width of the DNA fragment in which the original inhibitor 
was posed, a portion of minor and major grooves, and the active site residues of Topoisomerase I. 
The dimensions of the grids were thus 80×80×50, with a spacing of 0.200Å between the grid points 
and the center close to the cavity left by the ligand after its removal. The simpler intermolecular 
energy function based on the Weiner force field16 in Autodock was used to score the docking 
results. 
4.2.1 Hybrid QM/MM calculations. In the current study, we used the pseudo-bond ab-initio 
QM/MM approach as implemented in Gaussian-03 [35]. For the QM/MM calculations, the DNA-
Topoisomerase I-ligand system resulting from the docking study was first partitioned into a QM 
subsystem and an MM subsystem. The reaction system used a smaller QM subsystem consisting of 
the ligand and bases within 3.5Å, whereas the rest of the system (the MM subsystem) was treated 
using the AMBER force field, together with a low memory convergence algorithm. The boundary 
problem between the QM and MM subsystems was treated using the pseudo-bond approach. With 
this QM/MM system, an iterative optimization procedure was applied to the QM/MM system, using 
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BLYP/PW QM/MM calculations, leading to an optimized structure for the reactants. BLYP-STB 
and BP-STB calculations were carried out in order to check the dependence of the relative energies 
on the basis set and exchange correlation functional. The core electrons were frozen up to 4f for Pt, 
2p for Cl and 1s for N. For Pt, scalar relativistic effects were taken into account. The convergence 
criterion used was set to obtain an energy gradient of <10−4, using the twin-range cutoff method for 
non-bonded interactions, with a long-range cutoff of 14Å and a short-range cutoff of 8Å. 
4.3 Assessment of cytotoxic activity on human cancer cell lines. The non-small cell lung cancer 
H460 cell line, the squamous  carcinoma A431 cell line and the corresponding TPT-resistant 
A431/TPT and cisplatin-resistant A431/Pt sublines, the osteosarcoma U2OS cell line and the 
corresponding cDDP-resistant U2OS/Pt subline, the ovarian carcinoma IGROV-1 and A2780 cell 
lines and the corresponding Pt-resistant IGROV-1/Pt, IGROV-1/OHP and A2780/CP sublines were 
used. Cells were cultured in RPMI 1640 containing 10% FCS. Cytotoxicity was assessed by growth 
inhibition assay after a 1-h drug exposure. Compounds 1a, 1b, 6a and 6b were initially dissolved in 
dimetylsulphoxide and then diluted in sterile water. TPT and cDDP were dissolved and diluted in 
saline solution (0.9% sodium chloride).  Twenty-four hours after seeding in well plates (from 30 x 
103 to 120 x 103 cells/plate, depending on cell line), cells were exposed to the drugs and counted 72 
h later by a Coulter Counter. Each experimental sample was run in triplicate. The IC50 was defined 
as the drug concentration causing 50% cell growth inhibition determined by dose response curves 
generated by testing at least 5 different drug concentrations . Combination studies were performed 
using cDDP concentrations producing 80-90% of cell growth. 
4.4 Saccharomyces cerevisiae yeast strain and yeast spot test. JN2-134top1-1 S. cerevisiae strain 
(MATα rad52::LEU2, trp1, ade2-1, his7, ura3-52, ise1, top1, leu2), which lacks the endogenous 
TOP1 gene, was transformed with the empty vector (pEMBLyex4) or with the same vector 
containing the wild-type human DNA topoisomerase IB (pEZ-2hTop1) [36]. Yeast cells were 
maintained at 30°C in synthetic complete medium lacking uracil (uracil-) and supplemented with 
2% glucose. For the yeast spot test, cells were growth at 30°C in uracil medium to an OD595 of 0.3. 
The yeast culture was then treated with camptothecins or cisplatin for 24 h. After treatment, aliquots 
of 10 µl were spotted onto plate uracil-. Following 3 days of incubation at 30°C, images were 
acquired using the IMAGE MASTER VDS (Amersham Pharmacia Biotech). 
4.5 Topoisomerase I-dependent DNA cleavage assay. A 3’-end labeled gel purified 751-bp BamHI-
EcoRI fragment of SV40 DNA was used for the cleavage assay. SV40 plasmid was first linearized 
with BamHI enzyme and then 3’-labeled by using DNA polymerase I large (klenow) fragment 
(Invitrogen, Paisley, UK) in the presence of α32P dGTP. The labeled DNA was then restricted with 
EcoRI enzyme, and the corresponding 751-bp was purified on agarose gel. Topoisomerase I DNA 
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cleavage reactions (20,000 cpm/sample) were performed in 20 µl of 10 mM Tris–HCl (pH 7.6), 150 
mM KCl, 5mM MgCl2, 0.1 mM dithiothreitol, and human recombinant enzyme (full length 
topoisomerase I) for 30 min at 37°C.36 Reactions were stopped by 0.5% SDS and 0.3 mg/ml of 
proteinase K for 45 min at 42°C. Persistence of DNA cleavage at different time points was 
examined by adding 0.6 M NaCl after 30 min of incubation. After precipitation DNA was 
resuspended in denaturing buffer (80% formamide, 10 mM NaOH, 0.01 M EDTA and 1 mg/ml 
dyes) before loading on a denaturing 8% polyacrylamide gel in TBE buffer. Overall DNA cleavage 
levels were measured with a PhosphoImager 425 model (Molecular Dynamics). 
4.6 Drug accumulation studies. Exponentially growing H460 cells (1x106) were seeded in 5 cm 
diameter dishes in triplicate and, 24 h later, they were exposed to equitoxic (IC50) or equimolar (0.4 
µM) concentrations of the drugs for 1 h. After treatment, cell monolayers were washed with ice-
cold PBS, scraped, harvested and dissolved in 1 N NaOH. Total cellular Pt content was determined 
by flameless atomic absorption spectroscopy [37] (Model 3300, Perkin Elmer) or by inductively 
coupled plasma-mass spectrometry [38]. Cellular Pt levels were expressed as ng/106 cells, with cell 
number determined by counting parallel cultures. For each type of treatment at least three 
independent experiments were performed. 
4.7 DNA platination studies. Exponentially growing H460 cells (3x106) were seeded in 5 cm 
diameter dishes in triplicate and, 24 h later, they were exposed to the drugs for 1 h at equitoxic 
(IC50) or equimolar (0.4 µM) concentrations. DNA was then extracted according to standard 
procedures involving lysis in the presence of 1 mg/mL proteinase K overnight at 37°C. DNA was 
then isolated following phenol extraction, ethanol precipitation, RNase treatment, and 
reprecipitation and finally was dissolved in 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. DNA 
content was determined spectrophotometrically and platinum content was measured by flameless 
atomic absorption spectroscopy (Model 3300, Perkin Elmer) or by inductively coupled plasma-mass 
spectrometry. 
For the experiments with yeast cells, JN2-134top1-1 S. cerevisiae strain transformed with 
pEMBLyex4 or with pEZ-2hTop1 vectors was treated over night with 50 µM drug. Genomic DNA 
was obtained using MasterPure Yeast DNA purification kit (Epicentre biotechnologies, Wisconsin, 
USA) and the platinum content measured by inductively coupled plasma-mass spectrometry. 
For cell free experiments, pCMV6neo vector (10 µg sample) was treated for 1 h at 37°C with 
different compounds (50 µM) in the presence and absence of Topo I. After treatment, DNA was 
isolated following phenol extraction and ethanol precipitation. DNA concentration was determined 
spectrophotometrically, and platinum content was measured by flameless atomic absorption 
spectroscopy (Model 3300, Perkin Elmer). 
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4.8 DNA binding of camptothecins. EcoRV linearized pCMV6neo plasmid was used. Vector (200 
ng sample) and CPT analogues (50 µM sample) were incubated in 20 μl of 10 mM Tris–HCl (pH 
7.6), 150 mM KCl, 5 mM MgCl2, 0.1 mM dithiothreitol for 1 h at 37°C in the presence/absence of 
TopoI or BSA. After treatment, samples were loaded on 1% agarose gels or treated with 0.5% SDS 
and 0.3 mg/ml of proteinase K for 45 min at 42°C (where indicated) and then loaded on 1% agarose 
gel. The DNA plasmid migration was determined after the ethidium bromide staining. 
4.9 Antitumor activity. All experiments were carried out using female athymic Swiss nude mice, 7-
10 weeksold (Charles River, Calco, Italy). Mice were maintained in laminar flow rooms keeping 
temperature and humidity constant. Mice had free access to food and water. Experiments were 
approved by the Ethics Committee for Animal Experimentation of the Istituto Nazionale Tumori of 
Milan according to institutional guidelines. 
The compound was dissolved in DMSO/cremophor ELP. The solution was maintained at 4°C. 
Before the treatment, the drug solution was suspended in cold saline (5+2.5+92.5 of final volume) 
under magnetic stirring. Drug was delivered in a volume of 10 ml/kg of body weight. 
Cisplatinum Teva (clinical) was ready to use. Irinotecan was dissolved in sterile, distilled water 
keeping it under magnetic stirring for about 2 h. 
Exponentially growing tumor cells (107 cells/mouse) were s.c. injected into the right flank of 
athymic nude mice. The tumor line was achieved by serial s.c. passages of fragments (about 2x2x6 
mm) from growing tumors into healthy mice as previously described [39]. Tumor fragments were 
implanted on day 0, and tumor growth was followed by biweekly measurements of tumor diameters 
with a Vernier caliper. Tumor volume (TV) was calculated according to the formula: TV (mm3) = 
d2xD/2 where d and D are the shortest and the longest diameter, respectively. Drugs were delivered 
i.v. every fourth day for four times (q4dx4) starting when tumors were just palpable. The efficacy of 
the drug treatment was assessed as tumor volume inhibition percentage (TVI%) in treated versus 
control mice, calculated as: TVI% = 100-(mean TV treated/mean TV control x 100). The toxicity of 
the drug treatment was determined as body weight loss and lethal toxicity. Deaths occurring in 
treated mice before the death of the first control mouse were ascribed to toxic effects.  
4.10 Statistical analysis. Two-tailed Student’s t test was used for statistical comparison of drug 
uptake and DNA platination data as well as of tumor volumes in mice. 
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Captions to figures 
Figure 1. Retrosynthetic approach to compounds 1 
Figure 2. Interactions between the derivatives (2a and 2b, on the right) and the experimental DNA-
Topoisomerase I complex (left). The binding site is located inside the region delimited by the white 
rectangle (left) and the dotted green lines (right side) represent the intermolecular hydrogen bonds. 
 
Figure 3. Interactions between the Pt-derivatives (1a and 1b) and the experimental DNA- 
topoisomerase I complex. The main structural changes induced in the complex by the presence of 
platinum were observed at the level of the side chain, whereas the CPT ring maintained its position 
inside the DNA- topoisomerase I system. Again, the dotted green lines represent the intermolecular 
hydrogen bonds. 
 
Figure 4. (A) Graphic representation of the resistance indexes observed in the tested cell lines. The 
ratio between IC50 values of resistant and sensitive cells is reported for 1a and 1b. The resistant 
indexes of TPT and cDDP are reported for comparison. (B) Graphic representation of the ratio 
between the IC50 of the compound not containing Pt (6b or 6a) and the IC50 of the compound 
containing Pt (1b or 1a). A ratio higher than 1 (dashed line) indicates the positive effects produced 
by the Pt atom for drug potency. 
 
Figure 5. Interaction between camptothecins and cDDP. Antiproliferative activity of the 
combination was determined after a 1-h exposure to the camptothecin and cDDP using a cell 
counter. Dose-response curves for each CPT were determined in the presence of subtoxic 
concentrations of cDDP (10 µM; i.e., under conditions that did not produce antiproliferative effects 
of the cDDP). The combination index was calculated according to the method of Kern. S, 
synergism; A, antagonism. 
 
Figure 6. Topoisomerase I-mediated DNA cleavage by SN38 and CPT derivatives. Samples were 
reacted with 1, 10 and 50 μM drug at 37°C for 30 min. Reaction was then stopped by adding 0.5% 
SDS and 0.3 mg/mL of proteinase K and incubating for 45 min at 42°C before loading on a 
denaturing 8% polyacrylamide gel. C, control DNA; T, reaction without drug; M, purine markers. 
 
 
Figure 7. Persistence of topoisomerase I-mediated DNA cleavage in the presence of SN38 and 
camptothecin derivatives. Time-course analysis of DNA cleavage induced by SN38 and 
camptothecin analogs. The samples were reacted for 30 min with 1 μM drug. DNA cleavage was 
then reversed by adding 0.6 M NaCl. The 100% value refers to the extent of DNA cleavage at 30 
min of incubation. C, control DNA; T, reaction without drug. Cleavage persistence was measured 
by densitometric analysis.  Data represent mean values from  3 independent experiments.  
 
Figure 8. Cellular Pt accumulation and DNA platination in the H460 cell line. Platinum 
accumulation was determined after a 1-h exposure to equitoxic (IC50) (A) and equimolar (0.4 μM) 
(B) concentrations of cDDP and CPT derivatives. (C), DNA-bound platinum after a 1-h exposure to 
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equitoxic concentration (IC50) of cDDP and camptothecin derivatives. Accumulation was assessed 
by atomic absorption spectroscopy, and DNA platination was measured by inductively coupled 
plasma mass spectroscopy. Mean values (±SD) of triplicate determinations are shown. 
 
Figure 9. (A), sensitivity of S. cerevisiae JN2-134 strain in spot test. Yeast cells transformed with 
the empty vector (pEMBLyex4) or with the same vector containing the entire ORF of the human 
DNA topoisomerase I (pEZ-2hTop1) were used. Yeasts were grown to an A595 of 0.3 and then 
treated for 24 h with CPT derivatives at 1, 10 and 50 µM. Aliquots of 10 µl were spotted onto plates 
and incubated for 3 days at 30°C. Two references (CPT and cDDP) were included in the test. (B), 
DNA-bound platinum after overnight exposure of the transformed JN2-134 strain to 50 µM cDDP 
and CPT derivatives. After treatment, genomic DNA was extracted and Pt-DNA adducts were 
measured by inductively coupled plasma mass spectroscopy. Mean values (±SD) of triplicate 
determinations are shown. 
 
 
Figure 10. (A) DNA binding of CPT containing Pt. EcoRV linearized pCMV6neo plasmid (200 ng) 
and CPT analogues (50 µM) were incubated for 1 h at 37°C before loading on 1% agarose gel. 
Where indicated, before loading on agarose gel, samples were treated with 0.5% SDS and 0.3 
mg/ml of proteinase K. (B) Platination of pCMV6neo vector after exposure to CPT derivatives. 
pCMV6neo plasmid (10 µg sample) was treated for 1 h at 37°C with 50 µM of cDDP or 1b in the 
presence or absence of topoisomerase I. DNA concentration was determined spectrophotometrically 
and platinum content was measured by flameless atomic absorption spectroscopy. 
 
 
 
 
 
 
 
 
 
 
 
 28
 
Figure 1 
N
N
O
O
OOH
N
1a n = 1
1b n= 3
3a n = 1
3b n= 3
2a n = 1
2b n= 3
O NH
O
NH2
PtH2N
Cl
Cl
n
N
N
O
O
OOH
N
O NH
O
NH2
NH2
n
N
N
O
O
OOH
N
O NH2n
 
 
 
Figure 2  
 
 
 
 
 
 
 
 29
Figure 3 
 
 
 
 
Figure 4 
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0 6b/1b6a/1a
H4
60
A4
31
A4
31
T/
PT
A4
31
/P
t
IG
RO
V-
1
IG
R
O
V-
1/
Pt
IG
R
O
V-
1/
O
HP
A2
78
0
A2
78
0/
CP
U2
O
S
U2
O
S/
Pt
Ra
tio
A4
31
/T
PT
A4
31
/P
t
IG
RO
V-
1/
Pt
IG
RO
V-
1/
O
HP
A2
78
0/
CP
U2
O
S/
Pt
RI
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 TPT
cDDP
1a
1b
A B
H4
60
A4
31
A4
31
T/
PT
A4
31
/P
t
IG
RO
V-
1
IG
R
O
V-
1/
Pt
IG
R
O
V-
1/
O
HP
A2
78
0
A2
78
0/
CP
U2
O
S
U2
O
S/
Pt
Ra
tio
A4
31
/T
PT
A4
31
/P
t
IG
RO
V-
1/
Pt
IG
RO
V-
1/
O
HP
A2
78
0/
CP
U2
O
S/
Pt
RI
 
 
 
 
 
 
 
 
 30
Figure 5 
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Figure 7 
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Figure 8 
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Scheme 1. Reagents and conditions: (a) H2N-O-CH2CH2NH2. 2HCl, ethanol, Py, reflux, 1 h, 63%; (b) 
N,N-bis-t-butoxycarbonyl-2,3-diaminopropanoic acid, WSC, HOBt, DIPEA, DMF, rt, 2.5 h, 77%; (c) TFA/CH2Cl2 
1:1, from 0°C to rt, 3 h, quantitative; (d) K2PtCl4, H2O, N2, rt, 3h, 69%.
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Scheme 2. Reagents and conditions: (a) (Boc)2O, CH2Cl2, rt, overnight, 99%; (b) N-hydroxyphthalimide,
triphenylphosphine, DIAD, THF, from 0°C to rt, 1 h, 50%; (c) hydrazine hydrate, methanol, reflux, 1 h,
quantitative; (d) HCl 5.9M in ethyl acetate, ethyl acetate, 0°C, 1 h, 97%; (e) 4, Py, ethanol, reflux, 1 h,
77%; (f) N,N-bis-t-butoxycarbonyl-2,3-diaminopropanoic acid, WSC, HOBt, DIPEA, DMF, rt, 2.5 h, 65%; (g) 
TFA/CH2Cl2 1:1, from 0°C to rt, 3 h, quantitative; (h) K2PtCl4, H2O, N2, rt, 3h, 20%. (i)
cis-dichlorobis[(d,l)-diaminopropionic acid hydrochloride]platinum(II), EDC, TEA, DMF, rt, overnight,  89%.
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Table 1. Cellular sensitivity of human tumor cell lines to CPT derivatives a 
Cell line TPT cDDP 6a 1a 6b 1b 
H460 1.37±0.34 22±6.3 6.47±2.82 4.1±0.59 0.44±0.017 0.4±0.016 
U2OS 0.48±0.4 20.5±9.2 4.2±2.26 5.39±2.4 1.36±0.34 1.09±0.54 
U2OS/Pt 2.34±0.86 
(4.87) 
107.8±24 
(5) 
10.9±4.44 
(2.6) 
14.2±5.6 
(2.6) 
2.59±1.58 
(1.9) 
0.82±0.25 
(0.75) 
A431 0.075±0.067 19.57±1.37 0.99±0.35 1.68±0.29 0.28±0.099 0.185±0.035 
A431/TPT 0.29±0.01 
(3.86) 
16.84±2.19 
(0.86) 
8±1.4 
(8) 
14.2±0.28 
(8.4) 
2.87±1.94 
(10.3) 
1.23±0.89 
(6.6) 
A431/Pt 0.27±0.29 
(3.6) 
64.6±7.6 
(3.3) 
4.27±1.07 
(4.3) 
3.79±1.7 
(2.25) 
0.72±0.176 
(2.57) 
0.67±0.19 
(3.62) 
IGROV-1 1.03±0.8 14.8±2.54 17.8±4.5 5.79±0.29 2.24±0.3 1.24±0.077 
IGROV-1/Pt 3.9±0.96 
(3.9) 
211±19 
(14) 
11.8±1.42 
(0.66) 
14.2±10.2 
(2.5) 
4.1±2.14 
(1.8) 
3.03±1.32 
(2.4) 
IGROV-
1/OHP 
10.9±1.34 
(10.5) 
120.8±20 
(8) 
28±7.5 
(1.57) 
15.8±2.6 
(2.7) 
2.38±0.18 
(1.06) 
3.17±0.75 
(2.6) 
A2780 0.036±0.0035 4.35±0.49 0.69±0.44 2.16±0.23 0.08±0.028 0.22±0.064 
A2780/CP 0.275±0.01 
(7.6) 
41.5±9.2 
(9.5) 
2.55±0.35 
(3.7) 
4.8±1.4 
(2.2) 
0.79±0.45 
(9.8) 
0.73±0.31 
(3.3) 
 
aCell sensitivity to drug was assessed by growth-inhibition assay. Twenty-four h after seeding, cells were exposed to 
drug for 1 h and then, after an additional 72 h, counted using a cell counter. The reported value is the IC50 expressed in 
µM (drug concentration inhibiting growth by 50%). In parenthesis is reported the resistance index (ratio between IC50 
values of resistant and sensitive cells). Data represent mean values ± S.D. from at least 3 independent experiments.  
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Table 2. Antitumor activity of 1b against human H460 tumors xenografted s.c. in athymic nude 
mice. 
 
 
Compound 
Days of treatment Dose 
(mg/kg) 
TVI%a 
(20) 
BWL%b Toxc 
 
1b 3, 7, 11, 15 25 82 ** 0 0/6 
cDDP 3, 10, 17 5 58 ** 11 1/5 
Irinotecan 3, 7, 11, 15 60 88 ** 8 0/8 
 
aTumor volume inhibition % in treated over control mice; in parentheses the day it was assessed. Tumor 
fragments were implanted in both flanks at day 0. Treatment started when tumors were just palpable. CPTs 
were administered i.v. according to the q4dx4 schedule. cDDP was administered i.v. at the maximum 
tolerated dose and according to the schedule q7dx3. 
bBody weight loss % induced by drug treatment; the highest change is reported. 
cDead/treated mice. 
 **P<0.01 by two-tailed Student’ t test vs control mice. 
 
 
 
